• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial eff...
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: Abdul-Ghani, M.; Del Prato, S.; Chilton, R.; DeFronzo, R. A. Tags: Cardiovascular Disease and Diabetes Source Type: research

February Partner Spotlight
The Texas Diabetes Prevention and Control Program Incorporates NDEP Messages and Materials in its “Get Tested Today” Campaign The Texas Diabetes Prevention and Control Program (DPCP) at the Texas Department of State Health Services administers grant-funded initiatives and contracted services to address current issues affecting people with diabetes and those at risk of getting diabetes. The Texas DPCP maintains a statewide system of quality education services for all people with diabetes and health care professionals who offer diabetes treatment and educa...
Source: National Diabetes Education Program - January 31, 2014 Category: Endocrinology Source Type: news